PARKINSON'S DISEASE NEWS
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].
29th June 2014 - New research
COMPARISON OF L-DOPA, AGONISTS AND MAO INHIBITORS
Whether the initial treatment for Parkinson's disease should consist of L-dopa, dopamine agonists, or MAO B inhibitors is uncertain. So researchers aimed to establish which of these three classes of drug, as initial treatment, provided the most effective long-term control of symptoms and best quality of life for people with early Parkinson's Disease.
newly diagnosed with Parkinson's disease were randomly assigned between the
use of L-dopa, dopamine agonists and MAO B inhibitors. After three years
PDQ-39 mobility scores averaged 1·8 points better in people assigned to
L-dopa. PDQ-39 mobility scores were 1·4 points better in people assigned to
MAO B inhibitors when compared to those taking dopamine agonists. L-dopa was
not significantly advantageous for EQ-5D utility scores, dementia,
admissions to institutions, and death rates. Treatments were discontinued in
28% of those taking dopamine agonists, 23% of those taking MAOB inhibitors,
but only 2% of those taking L-dopa.
E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News, please merely e-mail [email protected] with the message "subscribe". No form of identity is required. E-mail addresses are not used for any other purpose.